EUCTR2012-002662-12-NLActive, not recruitingNot Applicable
An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects with Lesch-Nyhan Disease (LND).
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Psyadon Pharmaceuticals Inc.
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Subjects must have classic LND as defined by (a) characteristic clinical syndrome (evidence of overproduction of uric acid, severe generalized dystonia, frequent and persistent SIB, and cognitive impairment) and (b) laboratory confirmation for mutation of the HPRT gene or severe deficiency of the associated enzyme.
- •2. Subjects must have a minimum combined score of 20 on the BPI SIB subscales for frequency and severity as assessed by the caregiver.
- •3. Subjects must have a minimum score of 4 on the Physician?s Global Impression (PGI) severity scale.
- •4. Subjects must be ?6 years old.
- •5. Subject must have a body weight greater than 10 kg.
- •6. Although females with LND are extremely rare, they are occasionally encountered. For a woman to be eligible she must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for the duration of their participation in the study. Women of childbearing potential must agree to use contraception for 30 days after their last dose of study drug.
- •7. Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.
- •8. Subject and/or legal guardian must execute a written Informed Consent and/or Assent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 24
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. Subjects who have participated in a clinical trial (other than PSY101) and have received an investigational drug within 30 days prior to the start of the study.
- •2. Subjects who are on neuroleptics or dopamine depleting agents.
- •3. Subjects who are currently treated with medications for seizures
- •4. Subjects with impaired renal function as defined by a serum creatinine >1.5 mg/dL.
- •5. Subjects with medical comorbidities that may interfere with completion of the study.
- •6. Women of childbearing potential who are currently pregnant or lactating.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects with Lesch-Nyhan Disease (LND).Self-injurious behavior in subjects with Lesch-Nyhan Disease (LND).MedDRA version: 15.0Level: LLTClassification code 10024245Term: Lesch-Nyhan syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-002662-12-ESPsyadon Pharmaceuticals Inc.24
Withdrawn
Phase 3
An outpatient phase 3 efficacy study of Ecopipam (PSYRX 101) in the symptomatic treatment of self-injurious behavior in subjects with Lesch-Nyhan disease.zelfverwondend gedragHPRT gene mutationLesch-Nyhan disease1008362410028037NL-OMON37257Psyadon Pharmaceuticals Inc.5
Terminated
Phase 3
Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan DiseaseLesch-Nyhan DiseaseSelf-injurious BehaviorNCT01751802Emalex Biosciences Inc.9
Recruiting
Phase 1
Trial of the safety and efficacy of epcoritamab in Japanese subjects with R/R B-NHJPRN-jRCT2080225312Genmab US Inc.73
Unknown
Phase 2
Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).Stuttering, AdultChildhood-onset Fluency DisorderSpeech DisordersLanguage DisordersCommunication DisorderNCT02909088Gerald Maguire, MD10